Understanding the Market | HANSOH PHARMA opened nearly 2% higher, Goldman Sachs believes the company can promote or commercialize HS-10535 jointly in mainland China and Hong Kong-Macau or separately
HANSOH PHARMA's stock price opened nearly 2% higher and, as of the time of writing, has risen 1.96% to HKD 18.7. Goldman Sachs released a report stating that HANSOH PHARMA has signed a global exclusive licensing agreement with Merck & Co. to obtain the sales rights for the oral GLP-1 drug HS-10535. Goldman Sachs believes that the company can promote this product in mainland China and Hong Kong and Macau, and is optimistic about the global potential of its innovative product line. HANSOH PHARMA's GLP-1 product portfolio is comprehensive, with another oral GLP-1 drug HS-10501 already in clinical trials
According to Zhitong Finance APP, HANSOH PHARMA (03692) opened nearly 2% higher, and as of the time of writing, it rose 1.96% to HKD 18.7, with a transaction volume of HKD 1.9591 million.
Goldman Sachs released a research report stating that HANSOH PHARMA announced on December 18th a global exclusive licensing agreement with Merck for the global sales rights of the oral GLP-1 small molecule drug HS-10535, involving an upfront payment of USD 112 million, milestone payments of USD 1.9 billion, and royalties based on product sales. Goldman Sachs believes that HANSOH PHARMA can jointly promote or independently commercialize this product in mainland China and Hong Kong and Macau.
The firm noted that this is the second collaboration with a multinational company for HANSOH PHARMA in the past two years, having previously licensed two ADC drugs to GSK. The firm views positively the growing global potential of the company's innovative product line. Due to the increasing competition for oral GLP-1 drugs, Goldman Sachs has observed that more latecomers are attempting to seek differentiation in target selection and indication development. However, HANSOH PHARMA has developed a comprehensive GLP-1 product portfolio that includes both injectable and oral drugs, with another oral GLP-1 (HS-10501) already entering Phase I clinical trials. Goldman Sachs believes this drug also has licensing potential. The company plans to conduct Phase II studies in the first half of 2025